Cancer chemotherapy and pharmacology
-
Cancer Chemother. Pharmacol. · Aug 2015
Meta AnalysisPopulation pharmacokinetics of kahalalide F in advanced cancer patients.
In this study, we characterize the population pharmacokinetics of kahalalide F (KF), a novel marine anticancer drug, after intravenous (i.v.) administration in advanced cancer patients. ⋯ The integration of pharmacokinetic data from six clinical studies demonstrated KF linear elimination from plasma, dose-proportional exposure and time-independent pharmacokinetics. Based on analyzed data, no clinically relevant covariates were identified as predictors of KF pharmacokinetics.
-
Cancer Chemother. Pharmacol. · Aug 2015
Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma.
To determine the maximum recommended dose (RD) and pharmacokinetics of Myocet®, a non-pegylated liposomal doxorubicin, in children. ⋯ The RD of Myocet® administered every 3 weeks to paediatric patients was 60 mg/m(2). The efficacy of Myocet® in paediatric patients with high-grade glioma remains to be determined and should be studied in Phase II trials.